A phase I, open label, multi-center, dose escalation study of the safety, tolerability and pharmacokinetic properties of the orally administered negative enantiomer of Gossypol (AT-101) in patients with advanced malignancies
Phase of Trial: Phase I
Latest Information Update: 30 May 2009
At a glance
- Drugs AT 101 (Primary)
- Indications Cancer; Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- 30 May 2009 Interim pharmacokinetic data presented at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO-2009).
- 15 Aug 2006 New trial record.